{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:56:50Z","timestamp":1793239010074,"version":"4.5.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The tremendous success of chimeric antigen receptor (CAR) T cells in children and young adults (CAYAs) with relapsed\/refractory B-cell acute lymphoblastic leukemia is tempered by toxicities such as cytokine release syndrome (CRS). Despite expansive information about CRS, profiling of specific end-organ toxicities secondary to CAR T-cell therapy in CAYAs is limited. This retrospective, single-center study sought to characterize end-organ specific adverse events (AEs) experienced by CAYAs during the first 30\u00a0days after CAR T-cell infusion. AEs graded using Common Terminology Criteria for Adverse Events were retrospectively analyzed for 134 patients enrolled in 1 of 3 phase 1 CAR T-cell trials (NCT01593696, NCT02315612, and NCT03448393), targeting CD19 and\/or CD22. A total of 133 patients (99.3%) experienced at least 1 grade \u22653 (\u2265Gr3) AE across 17 organ systems, of which 75 (4.4%) were considered dose- or treatment-limiting toxicities. Excluding cytopenias, 109 patients (81.3%) experienced a median of 3\u00a0\u2265Gr3 noncytopenia (NC) AEs. The incidence of \u2265Gr3 NC AEs was associated with the development and severity of CRS as well as preinfusion disease burden (\u2265 25% marrow blasts). Although those with complete remission trended toward experiencing more \u2265Gr3 NC AEs than nonresponders (median, 4 vs 3), nonresponders experiencing CRS (n\u00a0= 17; 37.8%) had the highest degree of NC AEs across all patients (median, 7 vs 4 in responders experiencing CRS). Greater understanding of these toxicities and the ability to predict which patients may experience more toxicities is critical as the array of CAR T-cell therapies expand. This retrospective study was registered at www.clinicaltrials.gov as NCT03827343.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023009789","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T15:20:49Z","timestamp":1690212049000},"page":"5566-5578","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["A comprehensive analysis of adverse events in the first 30\u00a0days of phase 1 pediatric CAR T-cell trials"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2746-9410","authenticated-orcid":false,"given":"Sara K.","family":"Silbert","sequence":"first","affiliation":[{"name":"1Pediatric Oncology Branch, National Cancer Institute\/Center for Cancer Research, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna","family":"Madan","sequence":"additional","affiliation":[{"name":"2Center for Cancer Research, Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Holland","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, National Cancer Institute\/Center for Cancer Research, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"3Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Little","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, National Cancer Institute\/Center for Cancer Research, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Foley","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, National Cancer Institute\/Center for Cancer Research, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Epstein","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, National Cancer Institute\/Center for Cancer Research, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sarkisian","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, National Cancer Institute\/Center for Cancer Research, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3249-9796","authenticated-orcid":false,"given":"Daniel W.","family":"Lee","sequence":"additional","affiliation":[{"name":"4Division of Pediatric Hematology\/Oncology, Department of Pediatrics, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Nikitina","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, National Cancer Institute\/Center for Cancer Research, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Showri","family":"Kakumanu","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, National Cancer Institute\/Center for Cancer Research, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan","family":"Ruppin","sequence":"additional","affiliation":[{"name":"2Center for Cancer Research, Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneen","family":"Shalabi","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, National Cancer Institute\/Center for Cancer Research, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Yates","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, National Cancer Institute\/Center for Cancer Research, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, National Cancer Institute\/Center for Cancer Research, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"issue":"16","key":"2023092214050250300_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"10299","key":"2023092214050250300_bib2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"2023092214050250300_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2023092214050250300_bib4","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2023092214050250300_bib5","doi-asserted-by":"crossref","first-page":"e001511","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"2023092214050250300_bib6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2023092214050250300_bib7","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2023092214050250300_bib8","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2023092214050250300_bib9","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"25","key":"2023092214050250300_bib10","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2023092214050250300_bib11","doi-asserted-by":"crossref","first-page":"e001159","DOI":"10.1136\/jitc-2020-001159","article-title":"Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies","volume":"8","author":"Shalabi","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"8","key":"2023092214050250300_bib12","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","article-title":"Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience","volume":"24","author":"Burstein","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2023092214050250300_bib13","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/neuonc\/noac034","article-title":"Neurotoxicity following CD19\/CD28\u03b6 CAR T-cells in children and young adults with B-cell malignancies","volume":"24","author":"Shalabi","year":"2022","journal-title":"Neuro Oncol"},{"issue":"23","key":"2023092214050250300_bib14","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30\u00a0days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2023092214050250300_bib15","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"2023092214050250300_bib16","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2023092214050250300_bib17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/bloodadvances.2020002757","article-title":"Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy","volume":"5","author":"Buechner","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"2023092214050250300_bib18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T-cells in children and young adults with B-ALL: phase I results and development of a novel Bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023092214050250300_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"9967","key":"2023092214050250300_bib20","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T\u00a0cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"2023092214050250300_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1200\/JCO.22.01076","article-title":"Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia","volume":"41","author":"Schultz","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2023092214050250300_bib22","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"2023092214050250300_bib23","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1016\/S2352-3026(22)00168-5","article-title":"Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group","volume":"9","author":"Miller","year":"2022","journal-title":"Lancet Haematol"},{"issue":"2","key":"2023092214050250300_bib24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11899-021-00627-3","article-title":"Evolution of hematology clinical trial adverse event reporting to improve care delivery","volume":"16","author":"Miller","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"issue":"15","key":"2023092214050250300_bib25","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1200\/JCO.21.02669","article-title":"Lack of concordance in symptomatic adverse event reporting by children, clinicians, and caregivers: implications for cancer clinical trials","volume":"40","author":"Freyer","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023092214050250300_bib26","doi-asserted-by":"crossref","first-page":"e29986","DOI":"10.1002\/pbc.29986","article-title":"Longitudinal use of patient reported outcomes in pediatric leukemia and lymphoma reveals clinically relevant symptomatic adverse events","volume":"69","author":"Jacobs","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2023092214050250300_bib27","doi-asserted-by":"crossref","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"13","key":"2023092214050250300_bib28","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2023092214050250300_bib29","doi-asserted-by":"crossref","first-page":"e002287","DOI":"10.1136\/jitc-2020-002287","article-title":"Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia","volume":"9","author":"Levine","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"10","key":"2023092214050250300_bib30","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"issue":"9","key":"2023092214050250300_bib31","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"issue":"7","key":"2023092214050250300_bib32","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"suppl 3","key":"2023092214050250300_bib33","doi-asserted-by":"crossref","first-page":"S473","DOI":"10.1016\/S2666-6367(22)00781-3","article-title":"LBA1--CAR-associated hemophagocytic lymphohistiocytosis (HLH) with use of commercial tisagenlecleucel in the Pediatric Real World CAR Consortium (PRWCC): risk factors and outcomes","volume":"28","author":"McNerney","year":"2022","journal-title":"Transplantation and Cellular Therapy"},{"issue":"21","key":"2023092214050250300_bib34","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2023092214050250300_bib35","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/bloodadvances.2021006035","article-title":"Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy","volume":"6","author":"Holland","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2023092214050250300_bib36","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"2023092214050250300_bib37","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med"},{"issue":"24","key":"2023092214050250300_bib38","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2023092214050250300_bib39","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2023092214050250300_bib40","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1200\/JCO.2015.65.5860","article-title":"Accuracy of adverse event ascertainment in clinical trials for pediatric acute myeloid leukemia","volume":"34","author":"Miller","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023092214050250300_bib41","doi-asserted-by":"crossref","first-page":"e672","DOI":"10.1097\/PTS.0000000000000911","article-title":"Challenges and barriers to adverse event reporting in clinical trials: a children's oncology group report","volume":"18","author":"Miller","year":"2022","journal-title":"J\u00a0Patient Saf"},{"issue":"12","key":"2023092214050250300_bib42","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","article-title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial","volume":"20","author":"Laetsch","year":"2019","journal-title":"Lancet Oncol"},{"issue":"17","key":"2023092214050250300_bib43","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"2023092214050250300_bib44","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"15","key":"2023092214050250300_bib45","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2012-09-455063","article-title":"How I assess comorbidities before hematopoietic cell transplantation","volume":"121","author":"Sorror","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2023092214050250300_bib46","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"9","key":"2023092214050250300_bib47","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2010-08-303263","article-title":"Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients","volume":"117","author":"Smith","year":"2011","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/18\/5566\/2079927\/blooda_adv-2023-009789-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/18\/5566\/2079927\/blooda_adv-2023-009789-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T14:06:00Z","timestamp":1695391560000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/18\/5566\/497016\/A-comprehensive-analysis-of-adverse-events-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":47,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,9,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023009789","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]}}}